Paraneoplastic neurological syndrome: focus on the involvement of the peripheral nervous system

Bibliography:
1. Kanavos P. The rising burden of cancer in the developing world. Ann Oncol 2006; 17 (8): 15-23
2. Clouston PD, De Angelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 1992;31:268-273
3. Kanikannan MA, Sirisha Y, Uppin MS, et al. Incidence and spectrum of paraneoplastic neurological syndromes: single center study. J Neurooncol 2015; 125 (1): 197-206
4. Hu,ftberger R, Rosenfeld MR, Dalmau J. Update on Neurological Paraneoplastic Syndromes. Current opinion in oncology 2015; 27 (6): 489-495
5. Graus F, Delattre JY, Antoine JC, et al Recommended diagnostic criteria for paraneoplastic neurological syndromes Journal of Neurology, Neurosurgery & Psychiatry 2004; 75: 1135-1140
6. Dalmau J, Graus F. Paraneoplastic syndromes of the nervous system. Cancer of the nervous system / ed. J. S. Loeffler. Oxford: Blackwell Scientific Publications, 1997; p. 674-700
7. Kawasoe T, Yamamoto Y, Okumura Y, et al. A case report of paraneoplastic neurological syndrome associated with occult breast cancer. Breast Cancer 2006; 13 (2): 202-204
8. Grisold W, Grisold A. Cancer around the brain. Neuro-Oncology Practice 2014; 1 (1): 13-21
9. Greenberg HS, Deck MD, Vikram B, Chu FC, Posner JB. Metastasis to the base of the skull: clinical findings in 43 patients. Neurology 1981; 31: 530-537
10. Stillwagon GB, Lee DJ, Moses H, et al. Response of cranial nerve abnormalities in nasopharyngeal carcinoma to radiation therapy. Cancer 1986; 57: 2272-2274
11. Morita K, Kawabe Y Late effect on the eye of conformation radiotherapy for carcinoma of the paranasal sinuses and nasal cavity. Radiology 1979; 130 (1): 227-232
12. Peterson IA, Kriss JP, McDougall IR, et al. Prognostic factors in the radiotherapy of graeves ophthalmopathy. Int J Radiat Oncol Biol Phys 1990; 19: 259-264
13. Verschueren A, Gallard J, Boucraut J, et al. Paraneoplastic subacute lower motor neuron syndrome associated with solid cancer. Journal of the Neurological Sciences 2015; 358 (1 -2): 413-416
14. Grisold W, Grisold A, Loscher WN. Neuromuscular complications in cancer. Journal of the Neurological Sciences 2015; 367: 184-202
15. Chad DA, Recht LD. Neuromuscular complications of systemic cancer. Neurol Clin 1991; 9: 901-918
16. Kim HH, Kim YC, Park YH, et al. Cervicogenic headache arising from hidden metastasis to cervical lymph node adjacent to the superficial cervical plexus: A case report. Korean Journal of Anesthesiology 2001; 60 (2): 134-137
17. Babu MA, Spinner RJ, Dyck PJ, et al. Recurrent prostatic adenocarcinoma with perineural spread to the lumbosacral plexus and sciatic nerve: comparing high resolution MRI with torso and endorectal coils and F-18 FDG and C-11 choline PET/CT. Abdom Imaging 2013; 38 (5): 1155-60
18. Koroleva ES, Alifirova VM, Goldberg VE. Clinical, neurophysiological and immunological examination of cancer patients with peripheral nerve damage. Bulletin of Siberian Medicine 2012; 11 (3): 43-47
19. Seretny М, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014; 155:2461-2470
20. Semenova Al. Cardio- and neurotoxicity of antitumor drugs (pathogenesis, clinic, prophylaxis, treatment). Practical Oncology 2009; 10(3): 168-176
21. Hausbeer FH. Chemotherapy-induced peripheral neuropathy (Chapter 24). In: Perry MC, ed. The chemotherapy source book. 4th ed. Philadelphia: Lippincott Williams&Wilkins, 2008; p. 234-245
22. Green E, Sargent DJ, Goldberg LM, et al. Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741. Gl Cancer Symposium, Hollywood, FL, 2005; p. 27-29
23. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13 (1): 27-46
24. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology 2012; 14 (4): 54
25. Gregg RV, Molepo JM, Monpetit VJ. Cisplatin neurotoxicity: the relationship between dosage, time and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795-803
26. Schneider NA, Kantimirova EA. Paraneoplastic polyneuropathy: definition, etiology and pathogenesis, diagnosis. Siberian Health Review2010; 1:12-16
27. Grisold W, Drlicek М. Paraneoplastic neuropathy. Curr Opin Neurol 1999; 12(5): 617-625
28. Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Cane Netw 2006; 4 (6): 631-638
29. Belousov PV, Shebzukhov YuV., Nedospasov SA, et al. Onconeural antibodies as a tool in the diagnosis of malignant tumors and paraneoplastic neurologic syndromes. Molecular genetics, microbiology and virology 2007; 2: 6-13
30. Belyakov KM, Alyasova AV, Gustov AV. Features of the course of paraneoplastic polyneuropathies in patients with breast cancer. In: Neuroimmunology: Matherials of the X conference 2001; 2: 49
31. Filippov PP. Paraneoplastic antigens and early diagnosis of cancer. Soros Educational Journal 2000; 6 (9): 25-30
32. Graus F, Dalmau J. Paraneoplastic neurological syndromes. Current opinion in neurology 2012; 25 (6): 795-801
33. Darnell JC, Albert ML, Darnell RB. Cdr2 a target antigen of naturally occurring tumor immunity, is widely expressed in gynecologic tumors. Cancer Res 2000; 60 (21): 36-39
34. Graus F, Rowe G, Fueyo J, et al. The neuronal nuclear antigen recognized by the human anti-Ri autoantibody is expressed in central but not peripheral nervous system neurons. Neurosci Lett 1993; 150 (2): 12-14
35. Ansari J, Nagabhushan N, Syed R. Small cell lung cancer assotiated with anti-Hu paraneoplastic sensory neuropathy and peripheral nerve microvasculitis: case report and literature review. Clin Oncol 2004; 16 (1): 71-76
36. Koroleva ES, Goldberg VE, Simolina El, et al. The defeat of the peripheral nervous system of autoimmune and toxic genesis in patients with breast cancer after chemotherapy with cytostatics. In: Materials of the VII Congress of Oncologists and Radiologists of the CIS countries. Astana, 2012; p. 437-438
37. Antoine JC, Honnorat J, Camdessanche JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49: 214-221
38. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349: 1543-1554
39. Fong Ch.-Ch. Recent advance in immunological tests in paraneoplastic neurological syndrome. Acta Neurol Taiwan 2005; 14(1): 29-35
40. Ansari J, Nagabhushan N, Syed R, et al. Small cell lung cancer associated with anti-Hu paraneoplastic sensory neuropathy and peripheral nerve microvasculitis: case report and literature review. Clin Oncol 2004; 16 (1): 71-76.
41. Dalmau J, Rosenfeld MR. Update on paraneoplastic neurologic disorders. Oncologist 2010; 15 (6): 603-617
42. Koyama Y, Miyashita K, Anzai M, et al. Paraneoplastic neurologic syndrome and small-cell lung cancer in a patient positive for anti-Hu antigen. Nihon Kokyuki Gakkai Zasshi 2003; 41 (1): 35-38
43. Kuronuma K, Nishiyama K, Murakami S, et al. Small cell lung cancer associated with anti-Hu antibody-positive paraneoplastic neurologic syndrome. Nihon Kokyuki Gakkai Zasshi 2000; 38 (2): 148-152
44. Noto Y, Shiga K, Fujinami J, et al. Subacute sensory neuronopathy associated with squamous cell carcinoma of the lung: A case report. Rinsho Shinkeigaku 2009; 49 (8): 497-500.
45. Oh SJ, Gurtekin Y, Dropcho EJ, et al. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol 2005; 116 (1): 28-34
46. Ritzenthaler T, Verret JM, Honnorat J. Paraneoplastic chorea and behavioral disorders in a patient with anti-CV2/ CRMP5 antibodies and two different tumors. Rev Neurol (Paris). 2009; 166(1): 90-95
47. Levin OS. Polyneuropathies. M.: Med Inform Agentstvo, 2006; 496 p.
48. Grisold W, Piza-Katzer Н, Jahn R, et al. Intraneural nerve metastasis with multiple mononeuropathies. J Peripher Nerv Syst 2000; 5 (3): 163-167
49. Titulaer M J, Lang B, Verschuuren J J. Lambert — Eaton myasthenic syndrome: From clinical characteristics to therapeutic strategies. The Lancet Neurology 2011; 10 (12): 1098-1107
50. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: Clinical and serological observations in 29 cases. Ann Neurol 2012; 72: 241-255
51. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle and Nerve 2015; 51 (5): 638-656.